Why 70% of pharma partnership spend misses patients
Finding a start-up or building an app is the cheap part; combining capabilities into something that scales across markets is the expensive part.
Newsletters and Deep Dive digital magazine
Finding a start-up or building an app is the cheap part; combining capabilities into something that scales across markets is the expensive part.
Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.
pharmaphorum speaks with Thermo Fisher Scientific's Tina Liedtky about women in life sciences and leadership.
The gap between what CAR-T can do and who can actually get it is the defining challenge of this field right now.
The question for healthcare leaders is less whether AI has a role in surgical planning, and more how to implement it best.
Editor's Picks
Newsletters and Deep Dive
digital magazine